Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.75 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.59 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.59 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.59 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL634336 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL1262658 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL11226591 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL1262669 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL11210977 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL9641523 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL23682856 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL1260762 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL22151380 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL11224880 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115135323-A | Pharmaceutical composition | 深圳市药欣生物科技有限公司 | 2022-09-30 | — | — | CN | claimed |
| CN-104073901-B | The application in polyurethane composite fibre of the nitrogen containing plasma liquid | 杭州师范大学 | 2017-01-04 | — | — | CN | claimed |
| EP-4711502-A1 | ELECTROLYSIS DEVICE AND METHOD FOR MANUFACTURING ELECTROLYSIS DEVICE | KABUSHIKI KAISHA TOSHIBA (JP) | 2026-03-18 | — | — | EP | disclosed |
| EP-4527987-A2 | ELECTROLYSIS DEVICE | Kabushiki Kaisha Toshiba (JP) | 2025-03-26 | — | — | EP | disclosed |
| US-20250092548-A1 | ELECTROLYSIS DEVICE | KABUSHIKI KAISHA TOSHIBA (JP) | 2025-03-20 | — | — | US | disclosed |
| US-12018017-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-4350049-A2 | AMMONIA MANUFACTURING APPARATUS AND AMMONIA MANUFACTURING METHOD | KABUSHIKI KAISHA TOSHIBA (JP) | 2024-04-10 | — | — | EP | disclosed |
| US-20240110293-A1 | AMMONIA MANUFACTURING APPARATUS AND AMMONIA MANUFACTURING METHOD | KABUSHIKI KAISHA TOSHIBA (JP) | 2024-04-04 | — | — | US | disclosed |
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| CN-113382859-B | Surface protective film | 日东电工株式会社 | 2023-08-11 | — | — | CN | disclosed |
| WO-2005092854-A1 | BICYCLIC SUBSTITUTED INDOLE-DERIVATIVE STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005070916-A1 | THIOPHENE AND FURAN COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005066153-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2004067529-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
| CN-1061567-C | modified ion exchange resin and application thereof | MITSUBISHI CHEM CORP (JP) | 2001-02-07 | — | — | CN | disclosed |
| CN-1119129-A | modified ion exchange resin and application thereof | MITSUBISHI CHEM CORP (JP) | 1996-03-27 | — | — | CN | disclosed |
| US-4980346-A | N-ALKYL(ENE)-N-(O,O-DISUBSTITUTED-THIOPHOSPHORYL)-N',N' -SUBSTITUTED GLYCINE AMIDE DERIVATIVES | ESZAKMAGYARORSUAGI VEGYIMUVEK (HU) | 1990-12-25 | — | — | US | disclosed |
| US-4220764-A | Preparation of tertiary heterocyclic amines | UOP INC. (US) | 1980-09-02 | — | — | US | disclosed |
| US-4096150-A | Process for manufacture of tertiary amines | RHONE-PROGIL (FR) | 1978-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | HRH3 4292/4885GNAI3 525/4885GNAO1 1716/4885 |
| US-12018017-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, CASP1, BAX | HRH3 4103/4885GNAI3 1630/4885GNAO1 2416/4885 |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | HRH3 2171/4885GNAI3 1283/4885GNAO1 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.